Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Lewuillon C, Laguillaumie MO, Quesnel B, Idziorek T, Touil Y, Lemonnier L. Put in a “Ca2+ll” to Acute Myeloid Leukemia. Cells 2022;11:cells11030543. [PMID: 35159351 PMCID: PMC8834247 DOI: 10.3390/cells11030543] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/28/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open

For:	Lewuillon C, Laguillaumie MO, Quesnel B, Idziorek T, Touil Y, Lemonnier L. Put in a “Ca2+ll” to Acute Myeloid Leukemia. Cells 2022;11:cells11030543. [PMID: 35159351 PMCID: PMC8834247 DOI: 10.3390/cells11030543] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/28/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open

Number

Cited by Other Article(s)

Guardia GDA, Naressi RG, Buzzato VC, da Costa JB, Zalcberg I, Ramires J, Malnic B, Gutiyama LM, Galante PAF. Acute Myeloid Leukemia Expresses a Specific Group of Olfactory Receptors. Cancers (Basel) 2023;15:3073. [PMID: 37370684 DOI: 10.3390/cancers15123073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 05/23/2023] [Accepted: 05/31/2023] [Indexed: 06/29/2023] Open

Lewuillon C, Guillemette A, Titah S, Shaik FA, Jouy N, Labiad O, Farfariello V, Laguillaumie MO, Idziorek T, Barthélémy A, Peyrouze P, Berthon C, Tarhan MC, Cheok M, Quesnel B, Lemonnier L, Touil Y. Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. Int J Mol Sci 2022;23:ijms23105555. [PMID: 35628366 PMCID: PMC9141756 DOI: 10.3390/ijms23105555] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 12/19/2022] Open

Affiliation(s)

Clara Lewuillon CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Aurélie Guillemette CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Sofia Titah CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Faruk Azam Shaik Institut de Recherche sur le Cancer de Lille (IRCL), F-59000 Lille, France; LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan;
Nathalie Jouy UMS 2014/US41 Plateformes Lilloises En Biologie Et Sante, Université de Lille, F-59000 Lille, France;
Ossama Labiad CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Valerio Farfariello Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France
Marie-Océane Laguillaumie CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Thierry Idziorek CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Adeline Barthélémy CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Pauline Peyrouze CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Céline Berthon CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Mehmet Cagatay Tarhan LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan; CNRS, Centrale Lille, Junia, Université Polytechnique Hauts-de-France, UMR 8520—IEMN—Institut d’Electronique de Microélectronique et de Nanotechnologie, Université de Lille, F-59000 Lille, France
Meyling Cheok CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Bruno Quesnel CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
Loïc Lemonnier Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France Correspondence: loï (L.L.); (Y.T.)
Yasmine Touil CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.) Correspondence: loï (L.L.); (Y.T.)

Collapse

Immanuel T, Li J, Green TN, Bogdanova A, Kalev-Zylinska ML. Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential. Front Oncol 2022;12:1010506. [PMID: 36330491 PMCID: PMC9623116 DOI: 10.3389/fonc.2022.1010506] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Accepted: 09/21/2022] [Indexed: 02/05/2023] Open

Abstract

Intracellular calcium signaling regulates diverse physiological and pathological processes. In solid tumors, changes to calcium channels and effectors via mutations or changes in expression affect all cancer hallmarks. Such changes often disrupt transport of calcium ions (Ca²⁺) in the endoplasmic reticulum (ER) or mitochondria, impacting apoptosis. Evidence rapidly accumulates that this is similar in blood cancer. Principles of intracellular Ca²⁺ signaling are outlined in the introduction. We describe different Ca²⁺-toolkit components and summarize the unique relationship between extracellular Ca²⁺ in the endosteal niche and hematopoietic stem cells. The foundational data on Ca²⁺ homeostasis in red blood cells is discussed, with the demonstration of changes in red blood cell disorders. This leads to the role of Ca²⁺ in neoplastic erythropoiesis. Then we expand onto the neoplastic impact of deregulated plasma membrane Ca²⁺ channels, ER Ca²⁺ channels, Ca²⁺ pumps and exchangers, as well as Ca²⁺ sensor and effector proteins across all types of hematologic neoplasms. This includes an overview of genetic variants in the Ca²⁺-toolkit encoding genes in lymphoid and myeloid cancers as recorded in publically available cancer databases. The data we compiled demonstrate that multiple Ca²⁺ homeostatic mechanisms and Ca²⁺ responsive pathways are altered in hematologic cancers. Some of these alterations may have genetic basis but this requires further investigation. Most changes in the Ca²⁺-toolkit do not appear to define/associate with specific disease entities but may influence disease grade, prognosis, treatment response, and certain complications. Further elucidation of the underlying mechanisms may lead to novel treatments, with the aim to tailor drugs to different patterns of deregulation. To our knowledge this is the first review of its type in the published literature. We hope that the evidence we compiled increases awareness of the calcium signaling deregulation in hematologic neoplasms and triggers more clinical studies to help advance this field.

Collapse